Industry Symposium: Redefining your practice with infliximab biosimilar

Sponsored by

Program

Wednesday 10 April 2019
Time Topic Speaker
1030 – 1035 Welcome and Introduction
1035 – 1055 Biosimilar for treatment of rheumatologic disease
1055 – 1115 Drug retention of infliximab in Rheumatoid arthritis: Data from KOBIO
1115 – 1135 Future of infliximab: subcutaneous formulation
1135 – 1145 Panel Discussion All